NALTREXONE AS AN ADJUNCT TO TREATMENT OF SCHIZOPHRENIA: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SARDARPOUR GOUDARZI SH.; ARBABI MOHAMMAD; SAMIMI ARDESTANI S.M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Psychiatry and Clinical Psychology Year:2006 | Volume:12 | Issue:1 (44) Page(s): 49-54

Download Full-Text

Persian Verion

View:

1,079

Download:

Cites:

Information Journal Paper

Title

NALTREXONE AS AN ADJUNCT TO TREATMENT OF SCHIZOPHRENIA: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL

Author(s)

SARDARPOUR GOUDARZI SH. | ARBABI MOHAMMAD | SAMIMI ARDESTANI S.M. | Issue Writer Certificate

Keywords

SCHIZOPHRENIAQ3

NALTREXONEQ3

OPIOIDQ3

POSITIVE SYMPTOMSQ3

NEGATIVE SYMPTOMSQ3

MAINTENANCE THERAPYQ3

Abstract

Introduction: Given the role of OPIOIDs and their antagonists on dopamine secretion, the effect of NALTREXONE use in the treatment of SCHIZOPHRENIA was evaluated in this study. Method: In a double blind placebo controlled clinical trial study on a group of 34 patients with SCHIZOPHRENIA on MAINTENANCE THERAPY with antipsychotics, 17 patients received NALTREXONE (50 mg, BID) and 17 patients received placebo (BID). The patients were evaluated at the start of the trial, as well as three and six weeks after, using Positive and Negative Syndrome Scale (PANSS).Results: Patients receiving NALTREXONE showed improvement in POSITIVE SYMPTOMS from week three to week six, and improvement in NEGATIVE SYMPTOMS from week one to week three.Conclusion: NALTREXONE had no significant effect on positive or NEGATIVE SYMPTOMS of SCHIZOPHRENIA compared to placebo.

Cites

No record.

References

No record.

Cite

APA: Copy

SARDARPOUR GOUDARZI, SH., ARBABI, MOHAMMAD, & SAMIMI ARDESTANI, S.M.. (2006). NALTREXONE AS AN ADJUNCT TO TREATMENT OF SCHIZOPHRENIA: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL. IRANIAN JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY, 12(1 (44)), 49-54. SID. https://sid.ir/paper/16737/en

Vancouver: Copy

SARDARPOUR GOUDARZI SH., ARBABI MOHAMMAD, SAMIMI ARDESTANI S.M.. NALTREXONE AS AN ADJUNCT TO TREATMENT OF SCHIZOPHRENIA: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL. IRANIAN JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY[Internet]. 2006;12(1 (44)):49-54. Available from: https://sid.ir/paper/16737/en

IEEE: Copy

SH. SARDARPOUR GOUDARZI, MOHAMMAD ARBABI, and S.M. SAMIMI ARDESTANI, “NALTREXONE AS AN ADJUNCT TO TREATMENT OF SCHIZOPHRENIA: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL,” IRANIAN JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY, vol. 12, no. 1 (44), pp. 49–54, 2006, [Online]. Available: https://sid.ir/paper/16737/en

Related Journal Papers